irinotecan sucrosofate liposome + cyclophosphamide

This is a combination therapy consisting of two drugs: - **Irinotecan sucrosofate liposome** (also known as MM-398 or ONIVYDE) is a formulation of the topoisomerase I inhibitor irinotecan encapsulated in a lipid bilayer vesicle (liposome). This formulation prolongs plasma levels and intratumoral exposure to its active metabolite SN-38. Irinotecan inhibits topoisomerase I by stabilizing the DNA-topoisomerase I complex and preventing re-ligation of single-strand breaks during DNA replication, leading to double-strand breaks and cell death. The liposomal form allows for less frequent dosing and potentially fewer side effects compared to conventional formulations[1][2][4][5][8]. - **Cyclophosphamide** is an alkylating agent that crosslinks DNA strands through covalent bonding at guanine N7 positions. This leads to inhibition of DNA replication and transcription, resulting in cell death. The combination has been studied in early-phase clinical trials for pediatric brain tumors and sarcomas as well as other cancers[6][9][10]. The goal is often to leverage the complementary mechanisms—DNA damage via both topoisomerase inhibition (irinotecan) and alkylation (cyclophosphamide)—to enhance antitumor efficacy.

Other names

irinotecan hydrochloride liposomeirinotecan sucrosofateMM-398 + cyclophosphamide